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Herd effectsa b s t r a c t
Widespread introduction of rotavirus vaccines has led to major reductions in the burden of rotavirus gas-
troenteritis worldwide. Vaccine effectiveness is diminished, however, in low income countries, that har-
bour the greatest burden of rotavirus attributed morbidity and mortality. Indirect effects of rotavirus
vaccine (herd immunity and herd protection) could increase population level impact and improve vac-
cine cost effectiveness in such settings. While rotavirus vaccine indirect effects have been demonstrated
in high and middle income countries, there are very little data from low income countries where force of
infection, population structures and vaccine schedules differ. Targeted efforts to evaluate indirect effects
of rotavirus vaccine in low income countries are required to understand the total impact of rotavirus vac-
cine on the global burden of rotavirus disease.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Prior to the global roll-out of rotavirus vaccines, rotavirus gas-
troenteritis was responsible for 450,000 under-5 deaths each year,
over 95% of which occurred in GAVI Vaccine Alliance-eligible coun-
tries [1]. Clinical trials in high and middle income countries (HMIC)
of two globally licensed, live oral rotavirus vaccines (a monovalent
(RV1) and pentavalent (RV5) vaccine) demonstrated 85–100% effi-
cacy against severe rotavirus gastroenteritis, that has translated
into impressive effectiveness following their introduction into
national childhood immunisation programmes [2]. In low income
countries (LIC) vaccine efficacy was substantially lower (48–61%)
[3,4]; however in view of the high rotavirus gastroenteritis associ-
ated case fatality in these countries the WHO recommended rou-
tine implementation of rotavirus vaccine for infants as a global
priority. Since 2012, rotavirus vaccine has been introduced into
the infant immunisation schedules of more than 35 GAVI eligible
countries, with two or three doses given in early infancy for RV1
and RV5 respectively. Encouraging post-introduction findings have
recently been reported from sub-Saharan African countries with
RV1 effectiveness of 64% in Malawi, and a 61–70% reduction in
rotavirus attributable hospitalisations following introduction of
RV5 in Rwanda [5,6].
In addition to evaluating the direct effect of vaccines (protection
afforded directly to the individual by the vaccine), it is important
also to consider vaccine indirect effects when evaluating the total
impact of vaccination programmes. Indirect effects describe reduc-tion in disease burden due to changes in transmission resulting
from vaccination [7]; they can occur both in unvaccinated individ-
uals, and in addition to direct effects in vaccinated individuals [8].
Indirect effects of vaccines may result from horizontal transmis-
sion of vaccine leading to immune protection in unvaccinated con-
tacts (herd immunity) or reduction in transmission of wild-type
infection (herd protection) [9]. The latter may be generated via
two mechanisms; a reduction in number of infected cases with
subsequent reduced likelihood that susceptible community mem-
bers will come into contact with an infectious individual; and
through a reduction in the infectiousness of a vaccinated case if
they do acquire disease [10]. Some vaccines, for example measles
or rubella vaccines, provide herd protection only, while live, oral
vaccines such as rotavirus and oral poliovirus vaccine (OPV) can
provide both herd protection and herd immunity [9].
Indirect effects following rotavirus vaccination have been
reported from Europe [11–13], the USA [14], Latin America [15]
and Australasia [16], with a reduction in disease seen in unvacci-
nated young children, as well as vaccine age-ineligible groups
including infants under 2 months of age [17,18], and older children
and adults [19]. A review of data from several HMIC estimated a
median herd effect for infant rotavirus vaccine of 22% [20]. These
effects have been derived by comparing observed to expected vac-
cine impact, or by measuring reductions in disease burden in those
too old to have been vaccinated [11,19–21]. Although the precise
mechanisms of these observed indirect effects are not known, both
herd protection and herd immunity have potential to contribute. In
Taiwan, where qRT-PCR was used to detect rotavirus vaccine virus,
shedding was detected in up to 90% of recipients of a single dose of
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tal transmission of RV5 to siblings of vaccinated infants was
described in the US [23] and transmission of RV1 occurred in
19% of 100 sets of twins during a randomised controlled trial in
the Dominican Republic; approximately a quarter of whom devel-
oped anti-rotavirus IgA sero-conversion [24]. Regarding herd-
protection, wild-type rotavirus transmission is associated with
the presence of symptoms in the index case, and symptomatic
infants are thought to be crucial in introducing rotavirus infection
into households [25,26]. Additionally, rotavirus vaccine protects
maximally against severe disease, and severity of rotavirus diar-
rhoea has been shown to correlate with the quantity of virus shed
in the stool and the risk of transmission [25,27]. It is therefore
plausible that vaccine-induced reduction in either clinical disease
frequency or severity in young children might be expected to
reduce transmission of rotavirus in the community, though defini-
tive evidence of this is lacking.
As a result of the higher rotavirus disease burden and reduced
vaccine effectiveness in LICs, the occurrence of rotavirus indirect
vaccine effects would be particularly important, since additional
vaccine benefit would increase total population impact and
improve vaccine cost-effectiveness. This has been demonstrated
clearly with cholera vaccine, where re-analysis of clinical trials to
include evaluation of indirect effects showed that cholera vaccine
was not only cost effective, but has potential to have a significant
impact on the burden of endemic cholera [28,29]. However, with
the exception of recent observational data from Rwanda, there is
a lack of published evidence of rotavirus indirect effects from LICs
[6]. LICs differ from HMICs in burden of disease, presence of co-
morbidities such as HIV and malnutrition, vaccine effectiveness,
timing and coverage of vaccine schedules, and population struc-
tures. As a result it is uncertain whether and to what extent rota-
virus indirect effects will occur in these settings.
Accurate evaluation of vaccine indirect effects can be challeng-
ing, and this is especially true in low resource environments. Indi-
rect effects of vaccination programmes are typically estimated
using observational data after vaccine introduction; including pop-
ulation level disease surveillance, sero-surveys or case control
studies comparing odds of disease between contacts exposed to
vaccinated or unvaccinated individuals. Indirect effects can be
inferred if observed reductions in disease incidence are greater
than those anticipated given vaccine coverage and effectiveness,
but fully accounting for confounding in such observational studies
can be difficult. In addition, many LICs lack the systematic surveil-
lance systems required for adequate comparisons of disease rates
among unvaccinated groups, and large scale sero-surveys can be
problematic in settings where infra-structure is poor and sample
collection is not always acceptable to local communities. Case-
control studies can be difficult to conduct to a robust standard, par-
ticularly if laboratory confirmed endpoints are required.
Recently, study designs have been described which permit eval-
uation of indirect effects prospectively as part of clinical trials
before vaccine introduction [30]. Such designs could include
prospective cluster-randomised trials comparing disease incidence
among unvaccinated individuals within communities randomised
to receive vaccination or placebo, and step-wedge designs in which
vaccination is sequentially introduced into clusters or regions
allowing the as-yet unvaccinated cluster to act as a control [31].
Such studies represent an improvement on observational strate-
gies as they allow quantitative measurement of indirect effects
whilst minimising bias, but they are complex and expensive to
undertake and in the case of rotavirus it is now unethical to ran-
domise to placebo given recommendation for global introduction
and the demonstrated effectiveness of vaccination. However there
may still be scope for such studies, for example in situations where
sub-national vaccine introduction is planned. Halloran et al. [32]have argued that small units such as households or family units
can be used as an alternative to larger clusters, with disease rates
of household contacts in vaccinated units being compared to those
of household contacts in unvaccinated units. Such units can be
used to investigate overall indirect effects, or more specific compo-
nents of indirect effects such as vaccine effect on infectiousness or
transmission of vaccine type virus from vaccinated infants to
household members, and may be an efficient and pragmatic
approach to evaluating vaccine indirect effects in low-resource
settings [32].
All methods to evaluate vaccine indirect effects involve either
assessment of disease burden before and after vaccine introduc-
tion, assessment of vaccine impact at the time vaccine is intro-
duced, or the ability to assess a partially vaccinated community.
As increasing numbers of countries introduce rotavirus vaccine
into their routine infant schedules and achieve close to universal
coverage the window of opportunity to evaluate rotavirus vaccine
indirect effects in LICs is limited and it is important to ensure exist-
ing opportunities are not lost. International collaborations and tri-
angulation of data across multiple sites and different study designs
may be required. Mathematical models may be important to allow
incorporation of heterogeneous data, and to predict the contribu-
tion of indirect effects to rotavirus vaccine total impact.
Rotavirus vaccine programmes have made a substantial impact
on diarrhoeal disease in children in the poorest countries. However
to support ongoing policy development, particularly for countries
transitioning out of GAVI support, it is crucial that the overall pop-
ulation level effect of the vaccine is accounted for in assessments of
impact and cost-effectiveness.Funding
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